Intravenous Thrombolysis in Ischemic Stroke Patients with Intracranial Neoplasms: Two Cases and a Literature Review

Neil, William P; Ovbiagele, Bruce

doi:10.1155/2011/503758

Cited by 25 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neil and Ovbiagele 273 reported intravenous alteplase administration in 2 patients with a presumed acoustic neuroma in the cerebellopontine angle and an occipital falcine meningioma. Neither patient suffered a symptomatic intracranial hemorrhage.…”

Section: Intracranial Neoplasmsmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

568

237

View full text Add to dashboard Cite

Purpose-To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke. Methods-Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee and the American Heart Association's Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiology studies, morbidity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize existing evidence and to indicate gaps in current knowledge and, when appropriate, formulated recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on and approved the final version of this document. The document underwent extensive American Heart Association internal peer review, Stroke The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 24, 2015, and the American Heart Association Executive Committee on October 5, 2015. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@ wolterskluwer.com.The online-only Data Supplement, which contains literature search strategies and Figures A, B, and C, is available with this article at http://circ. ahajournals.org/lookup/suppl/doi:10.1161/STR.0000000000000086/-/DC1.The American Heart Association requests that this document be cited as follows: Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rational...

show abstract

Section: Intracranial Neoplasmsmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

568

237

View full text Add to dashboard Cite

show abstract

“…Besides confirmation of the stroke, knowledge of the premorbid diagnosis of brain tumor is a vital factor influencing the decision to administer thrombolysis. Previously published case reports show that thrombolysis was administered to patients with known pre-existing diagnosis of benign brain tumors, particularly meningiomas and schwannomas [21,22], while patients with malignant BTS were mostly undiagnosed at the time of thrombolysis [23,24]. One may speculate that physicians may be more inclined to administer thrombolysis in the setting of a known diagnosis of a benign brain tumor, as opposed to a malignant brain tumor.…”

Section: Discussionmentioning

confidence: 99%

In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors

Murthy

Moradiya

Shah

et al. 2015

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…In the literature, the use of IV tPA for AMI or PTE has been reported in nearly twenty patients with GBM and intra-tumoral bleeding was not observed (16). No tumoral bleeding was reported in over 30 patients with extra-axial tumors (acoustic neuroma, meningioma) who were treated with IV tPA for ischemic stroke (82). Except for special conditions, administration of IV tPA is not contraindicated in extra-or intra-axial primary brain tumors.…”

Section: Question: Can IV Tpa Be Administered If There Is a Brain Tumor?mentioning

confidence: 99%

Intravenous Thrombolytic Therapy in Acute Stroke: Problems and Solutions

Topçuoğlu¹,

Arsava²,

Özdemi̇r³

et al. 2017

tnd

View full text Add to dashboard Cite

162Use of intravenous tissue plasminogen activator (tPA) is one of the key elements of acute ischemic stroke management. Its use has not become widespread, and has faced significant problems in our country for more than a quarter of a century most probably due to many unanswered questions about issues related with daily practice. However, recent developments, which adequately focused and found solutions for most of these problems and questions, have led to a major change of point of view and understanding of the hyperacute management of stroke. This article, in the light of the relevant literature, discusses and provides clear recommendations for questions directed by neurologists practicing in Turkey mainly about typical neurologic issues faced in the setting of tPA use for acute stroke.Keywords: Stroke, thrombectomy, contraindication, avoidance, training Akut iskemik inme tedavisinin kritik elementlerinin başında gelen intravenöz doku plazminojen aktivatörü (tPA) kullanımının yirmi yılı aşkın süre içinde ülkemizde yeterince yaygınlaşamamasının başta gelen nedenlerinden biri, kullanımına dair birçok sorunun yanıtsız kalmasıdır. Ancak, son gelişmeler ile bu soruların pek çoğuna yeterli açıklamanın getirilebilmiş olması önemli bir anlayış değişikliğine yol açmaktadır. Bu makalede akut inmede tPA tedavisi ile ilgili uzmanlarımızın yönelttiği birincil olarak nörolojik sorulara ilişkin yanıt ve açıklamalar mevcut literatür ışığında etraflıca ele alınmış ve herbiri için net tavsiyelerde bulunulmuştur.Anahtar Kelimeler: Strok, trombektomi, kontrendikasyon, kaçınma, eğitim Abstract Öz

show abstract

Intravenous Thrombolysis in Ischemic Stroke Patients with Intracranial Neoplasms: Two Cases and a Literature Review

Cited by 25 publications

References 8 publications

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors

Intravenous Thrombolytic Therapy in Acute Stroke: Problems and Solutions

Contact Info

Product

Resources

About